Investors

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

2014 News Releases

Webcast ImageWebcast
Q4 2016 Portola Pharmaceuticals, Inc. Earnings Conference Call (Live)
02/28/17 at 1:30 p.m. PT
Q4 2016 Portola Pharmaceuticals, Inc. Earnings Conference Call
Tuesday, February 28, 2017 1:30 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
11/17/14Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)
-- Andexanet Alfa Rapidly Reversed the Anticoagulant Effect of the Factor Xa Inhibitor Eliquis (apixaban) Among All Study Participants -- -- Data Presented Today during American Heart Association 2014 Scientific Sessions: "Clinical Science: Special Reports" Session -- SOUTH SAN FRANCISCO, Calif., PRINCETON, N.J., and NEW YORK, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA), Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced resul... 
Printer Friendly Version
11/10/14Portola Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today provides a corporate update and reports its financial results for the quarter ended September 30, 2014. "The third quarter marked another successful period of execution for Portola as we achieved a number of milestones across our three wholly-owned clinical programs. We announced positive Phase 3 study results with our universal Factor Xa inhibitor... 
Printer Friendly Version
11/06/14Portola Pharmaceuticals Announces Upcoming Presentations at the American Society of Hematology 2014 Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that its programs in thrombosis and hematology will be highlighted in poster sessions at the upcoming American Society of Hematology (ASH) Annual Meeting, which is taking place from December 6-9 in San Francisco. Presentations will include results from a Phase 2 proof-of-concept study of andexanet alfa, an FDA-designated breakthrough therapy and potential first-in-class Factor Xa i... 
Printer Friendly Version
11/06/14Portola Pharmaceuticals to Present at the Credit Suisse 2014 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, at 9:30 a.m. Mountain Time in Phoenix. The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section. About Portola Pharmaceuticals, Inc. Portola Pharmaceuticals i... 
Printer Friendly Version
11/03/14Portola Pharmaceuticals to Announce Third Quarter 2014 Financial Results and Host Conference Call on Monday, November 10, 2014
SOUTH SAN FRANCISCO, Calif., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended September 30, 2014 and provide a general business overview on Monday, November 10, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Conference Call Details To access the live conference call, please dial (877) 415-3183 from the U.S. and Canada, or +1(857)... 
Printer Friendly Version
10/16/14Portola Pharmaceuticals Announces Commercial Supply Agreement for Andexanet Alfa With Lonza
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it has executed a supply agreement with Lonza for the commercial manufacturing of andexanet alfa. An FDA-designated breakthrough therapy, andexanet alfa is the only recombinant Factor Xa molecule designed to specifically reverse the effects of oral and injectable Factor Xa inhibitors. It is being developed as an antidote for patients receiving one of these anticoagulants who ... 
Printer Friendly Version
10/02/14Portola Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today the pricing of its underwritten public offering of 6,200,000 shares of its common stock at a price to the public of $26.00 per share. In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 930,000 shares from Portola at the public offering price. The offering is expected to close on October 8, 2014, subject to customary... 
Printer Friendly Version
10/01/14Portola Pharmaceuticals Announces Proposed Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it has commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of approximately $160,000,000. All of the shares of common stock in the offering will be sold by Portola Pharmaceuticals. Subject to market and other conditions, the offering is expected to price before 9:30 a.m., EDT, on October 3, 2014. Morgan Stanley and... 
Printer Friendly Version
10/01/14Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance
Detailed Data Showing Andexanet Alfa Significantly Reversed Anticoagulation Activity of Factor Xa Inhibitor Eliquis to be Featured at American Heart Association's "Clinical Science: Special Reports" Session on November 17 SOUTH SAN FRANCISCO, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that its first Phase 3 study of andexanet alfa, a potential universal Factor Xa inhibitor antidote and U.S. Food and Drug Administration-designated breakthrough ... 
Printer Friendly Version
09/02/14Portola Pharmaceuticals to Present at the 2014 Morgan Stanley Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the 2014 Morgan Stanley Global Healthcare Conference on Tuesday, September 9, at 2:55 p.m. Eastern Time in New York City. The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section. About Portola Pharmaceuticals, Inc. Portola Pharm... 
Printer Friendly Version
08/06/14Portola Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today provides a corporate update and reports its financial results for the quarter ended June 30, 2014. "We had a productive quarter and achieved a number of important milestones to advance our three wholly-owned and potentially groundbreaking products. For betrixaban, our oral Factor Xa anticoagulant, we had our highest quarterly enrollment to date in o... 
Printer Friendly Version
07/30/14Portola Pharmaceuticals to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 2014
SOUTH SAN FRANCISCO, Calif., July 30, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended June 30, 2014 and provide a general business overview on Wednesday, August 6, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Conference Call Details To access the live conference call, please dial (877) 299-4454 from the U.S. and Canada, or +1(6... 
Printer Friendly Version
07/07/14Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo for Phase 3 Studies of Factor Xa Inhibitor Antidote, Andexanet Alfa, and Edoxaban
-- Phase 3 Collaboration Agreements in Place With All Direct Factor Xa Inhibitor Manufacturers While Portola Retains All Rights to Andexanet Alfa -- SOUTH SAN FRANCISCO, Calif., July 7, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it has entered into a second clinical collaboration agreement with Daiichi Sankyo to study andexanet alfa, Portola's investigational Factor Xa inhibitor antidote, in Phase 3 registration studies with Daiichi Sankyo's Factor Xa... 
Printer Friendly Version
06/12/14Portola Pharmaceuticals to Present at the 2014 Wells Fargo Securities Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 12, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the 2014 Wells Fargo Securities Healthcare Conference on Wednesday, June 18, at 8:20 a.m. Eastern Time in Boston. The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section. About Portola Pharmaceuticals, Inc. Portola Pharmaceutica... 
Printer Friendly Version
06/11/14Portola Pharmaceuticals Announces Positive Phase 2 Data With FDA-Designated Breakthrough Therapy Andexanet Alfa and Enoxaparin
--Data Extend the Potential for Andexanet as an Antidote Beyond Oral Factor Xa Inhibitors to Injectible Low Molecular Weight Heparin-- SOUTH SAN FRANCISCO, Calif., June 11, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that a Phase 2 proof-of-concept study in healthy volunteers demonstrated that andexanet alfa, a potential first-in-class Factor Xa inhibitor antidote, immediately reversed the anticoagulation activity of enoxaparin, a low molecular we... 
Printer Friendly Version
05/14/14Portola Pharmaceuticals Announces Two Presentations of Data on Cerdulatinib, an Oral Dual Syk/JAK Inhibitor, at 2014 ASCO Annual Meeting
--Initial Phase 1 Doses Associated with High Levels of Syk and JAK Inhibition–  --Activity in Cell Lines with CARD11 Mutation May Further Differentiate Cerdulatinib-- SOUTH SAN FRANCISCO, Calif., May 14, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced two upcoming data presentations on cerdulatinib*, the Company's novel, oral, dual Syk-JAK kinase inhibitor, at the upcoming American Society of Clinical Oncology (ASCO) 50th Annual Meeting, which i... 
Printer Friendly Version
05/12/14Portola Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today provided a corporate update and reported its financial results for the quarter ended March 31, 2014. "We have had a very productive quarter, and we remain confident we can achieve our goal of bringing to market our three wholly-owned treatments for patients with blood clots and blood cancers," said William Lis, chief executive officer of Portola. "O... 
Printer Friendly Version
05/12/14Portola Pharmaceuticals Begins Enrollment in Phase 3 Study of FDA-Designated Breakthrough Therapy Andexanet Alfa and Factor Xa Inhibitor XARELTO(R)
Second Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, to be Conducted Under Accelerated Approval Pathway SOUTH SAN FRANCISCO, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that enrollment has begun in a Phase 3 study to evaluate the safety and efficacy of andexanet alfa, the Company's investigational recombinant Factor Xa inhibitor reversal agent, with Bayer HealthCare and Janssen Pharmaceuticals ... 
Printer Friendly Version
05/12/14Portola Pharmaceuticals to Present at Bank of America Merrill Lynch 2014 Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas on Thursday, May 15, 2014, at 10:00 a.m. Pacific Time. The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section. About Portola Pharmaceuticals, Inc. Portol... 
Printer Friendly Version
05/05/14Portola Pharmaceuticals to Announce First Quarter 2014 Financial Results and Host Conference Call on Monday, May 12, 2014
SOUTH SAN FRANCISCO, Calif., May 5, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended March 31, 2014 and provide a general business overview on Monday, May 12, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Conference Call Details To access the live conference call, please dial (866) 515-2912 from the U.S. and Canada, or +1(617) 39... 
Printer Friendly Version
04/14/14Portola Pharmaceuticals Announces Publication of Phase 3 APEX Study Design and Rationale in American Heart Journal
Global, Pivotal Phase 3 APEX Study of Betrixaban Enrolling Acute Medically Ill Patients Using Biomarker-Based Strategy to Identify Those Most Likely to Benefit From Therapy SOUTH SAN FRANCISCO, Calif., April 14, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced publication of the design and rationale of the Phase 3 APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) Study in the March 2014 issue of the American Heart Journal.i Betrixaban, the... 
Printer Friendly Version
03/27/14Portola Pharmaceuticals Initiates Phase 2 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, and Factor Xa Inhibitor Edoxaban
SOUTH SAN FRANCISCO, Calif., March 27, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it has initiated a Phase 2 proof-of-concept study to evaluate andexanet alfa, the company's investigational Factor Xa inhibitor reversal agent, as a reversal agent for Daiichi Sankyo's oral, once-daily, direct Factor Xa inhibitor edoxaban in healthy volunteers. Portola is developing andexanet alfa, an FDA-designated breakthrough therapy, as a potential first-in-class antidot... 
Printer Friendly Version
03/19/14Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway
FDA-Designated Breakthrough Therapy is Portola's Second Drug to Enter Phase 3 Development SOUTH SAN FRANCISCO, Calif., March 19, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it has initiated a Phase 3 study of andexanet alfa, the company's investigational Factor Xa inhibitor reversal agent. The study will evaluate the safety and efficacy of andexanet alfa with Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc.'s (NYSE: PFE) Factor Xa inhibitor Eliqui... 
Printer Friendly Version
03/18/14Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
SOUTH SAN FRANCISCO, Calif., March 18, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced the appointment of John H. Johnson to its board of directors effective March 26, 2014. Mr. Johnson currently serves as chairman, president and chief executive officer of Dendreon Corporation. "We're thrilled to add John, a prestigious industry leader, to the Portola Board. John's strategic capabilities and his experience in oncology and biologics manufacturing will serve Portola... 
Printer Friendly Version
02/27/14Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update
Conference Call Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced a corporate update and reported its financial results for the fourth quarter and year ended December 31, 2013. "2013 was a very successful year for Portola. We executed on a series of important milestones in pursuit of our goal of building an enduring biopharmaceutical company and bringing to market three wholly-owned and potentially grou... 
Printer Friendly Version
02/24/14Portola Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the Cowen and Company 34th Annual Health Care Conference on Monday, March 3, 2014, at 2:10 p.m. Eastern Time in Boston. The presentation will be webcast live and available for replay from Portola's website at www.portola.com in the Investor Relations section. About Portola Pharmaceuticals, Inc. Portola Pharmaceuticals ... 
Printer Friendly Version
02/20/14Portola Pharmaceuticals to Announce Fourth Quarter and Year End 2013 Financial Results and Host Conference Call on Thursday, February 27, 2014
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter and year ended December 31, 2013, and provide a general business overview on Thursday, February 27, 2014, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Conference Call Details To access the live conference call, please dial (866) 318-8611 from the U.S. and Canad... 
Printer Friendly Version
02/03/14Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Bayer and Janssen for Phase 3 Studies of Andexanet Alfa*, Investigational Factor Xa Inhibitor Reversal Agent, and XARELTO(R)
Portola to Receive Upfront and Milestone Payments While Retaining Full Worldwide Rights to Andexanet Alfa SOUTH SAN FRANCISCO, Calif., Feb. 3, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it has entered into a second clinical collaboration agreement with Bayer HealthCare and Janssen Pharmaceuticals, Inc. to evaluate its investigational Factor Xa inhibitor reversal agent, andexanet alfa*, in Phase 3 registration studies with the U.S. Food and Drug Administr... 
Printer Friendly Version
01/13/14Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis
Portola to Receive Upfront and Milestone Payments While Retaining Full Worldwide Rights to Andexanet Alfa SOUTH SAN FRANCISCO, Calif., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it has entered into a second clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) to study Portola's investigational Factor Xa inhibitor reversal agent, andexanet alfa* (PRT4445), with the oral Factor Xa inhibitor Eliqu... 
Printer Friendly Version
01/06/14Portola Pharmaceuticals Announces Webcast of Corporate Presentation on January 13, 2014
SOUTH SAN FRANCISCO, Calif., Jan. 6, 2014 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that it will host an investor webcast and conference call on Monday, January 13, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) coinciding with the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco. During the event, Portola's senior management team will provide an update on the Company's recent business progress. To access the live conference call, please dial (... 
Printer Friendly Version